Skip to main content
. 2021 Mar 15;7:48. doi: 10.1038/s41420-021-00439-7

Fig. 1. NP-011 reduces TGF-β1-induced fibrosis in AOs.

Fig. 1

A qPCR of the indicated fibrosis-related genes in control AOs and AOs with TGF-β1 (25 ng/ml)-induced fibrosis. B Representative images show Sirius red and α-SMA staining of AO sections from the indicated groups. Scale bars, 100 μm. C, D Western blotting (C) and subsequent quantification of p-ERK, p-SMAD2/3, and Collagen (D) in AOs from the indicated groups. Actin was used as a loading control. E qPCR analysis for expression of TGF-β1, COL1A1 and IL-11 from the indicated groups. F Western blot analysis for p-ERK in human pAECs incubated with TGF-β1 (25 ng/ml) or TGF-β1 and NP-011 (500 ng/ml) for 72 h. Actin was used as loading control. G FMT assay using pulmonary fibrosis patient-derived fibroblasts. The upper panel shows the overall procedure for FMT assay, and the low panel indicates the quantified data from high-content analysis (HCA). Left axis and blue dots indicate the percentage of inhibition (PIN) of TGF-β1-mediated α-SMA expression in patient fibroblasts by NP-011 treatment, and the right axis and orange dots indicate the percentage of remaining cells after NP-011 treatment in patient fibroblast. Data are presented as means ± SD from three independent experiments. *p < 0.05, **p < 0.01 (ANOVA).